1. A spacer region between the single chain antibody-and the CDS -chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity.;Gene Ther,1995
2. Engineering T cells for cancer: our synthetic future.;Immunol Rev,2014
3. Chimeric T cell receptor which incorporates the anti-tumour specificity of a monoclonal antibody with the cytolytic activity of T cells: a model system for immunotherapeutical approach.;Br J Cancer Suppl,1990
4. Adoptive cell therapy for the treatment of patients with metastatic melanoma.;Curr Opin Immunol,2009
5. Tumor-specific allogeneic cells for cancer therapy.;Exp Opin Biol Ther,2011